NEW YORK, July 17, 2026 – Shares of AtaiBeckley Inc. (NASDAQ:ATAI) are reflecting a market valuation for merger rights that amounts to approximately 14% of their face value, according to premarket trading data. The stock was priced at $7.091 ahead of Friday's session, down 0.8% from the previous close.
The current share price sits 34 cents above Eli Lilly and Co.'s (NYSE:LLY) $6.75 cash offer, a spread that represents the market's implied pricing of a contingent value right (CVR) tied to the merger. This CVR offers up to $2.50 per share in potential milestone payments, but it will not be traded and is mostly non-transferable, making this a non-standard cash merger spread.
Deal Structure and Milestones
Eli Lilly announced on Thursday that it will pay approximately $2.8 billion upfront for AtaiBeckley, with the total deal value potentially reaching $3.8 billion if all milestones are achieved. The closing is expected in the third quarter, pending shareholder and regulatory approvals. The CVR comprises three potential payments: $1.00 per share upon initiation of a Phase 3 study for VLS-01 within four years, $0.50 per share upon U.S. approval and DEA rescheduling of BPL-003 within five years, and $1.00 per share upon U.S. approval and DEA rescheduling of VLS-01 within seven years.
The market-implied CVR value of $0.341 per share represents 13.6% of the maximum $2.50 face value. This figure is not an implied probability of success, as each payout is subject to distinct risks and timing conditions, including clinical and regulatory hurdles over a four- to seven-year period.
Market Context and Volume
AtaiBeckley's stock ended Thursday at $7.15, a 33.4% gain, with an extraordinary 166 million shares traded. This volume was 18.5 times the daily average between July 6 and July 10. The share price has risen 38.3% since last Friday's close, after a 0.4% decline the prior week. The active trading underscores investor interest in the deal's upside potential, despite the long-term nature of the CVR.
Shares of GH Research plc (NASDAQ:GHRS), a peer developing mebufotenin for treatment-resistant depression, rose 7.9% on Thursday. This moderate increase signals a sector read-through rather than a wholesale repricing of similar companies, as the market digests the implications of Eli Lilly's entry into the psychedelic therapy space.
Analyst Perspectives
Jefferies analyst Andrew Tsai forecasts potential sales for BPL-003 between $1 billion and $2 billion if late-stage trials succeed, with first data expected in early 2029. Barclays analyst Emily Field noted that the deal provides "upside potential in large markets like depression," highlighting the strategic value for Eli Lilly.
BPL-003 is a synthetic 5-MeO-DMT therapy administered intranasally, targeting resistant depression. VLS-01 is a buccal DMT film currently in Phase 2b trials. Both assets represent high-risk, high-reward opportunities in the mental health space.
Voting and Risks
Investors are awaiting details on the preliminary proxy and voting schedule. Early Friday, AtaiBeckley's filings page listed an 8-K and a DEFA14A, but no preliminary proxy had been filed. Voting agreements account for roughly 15% of outstanding shares, but the deal requires a majority of all outstanding shares for approval, meaning the reported support block does not eliminate the risk of failing to secure enough votes.
Key risks include shareholders voting down the merger, regulatory delays, and the possibility that clinical or regulatory milestones may not be achieved, resulting in no payout for the untraded CVRs. The outside date for closing is six months, with a possible extension to nine months for certain regulatory delays.
As of Friday's close, cash remains the benchmark, while the CVRs represent illiquid, long-term biotech bets. Investors are pricing in a cautious view of the potential milestones, reflecting the inherent uncertainties in drug development and regulatory approval.
